Feds, Pharma Companies Strike Deal for Low Cost GLP-1 Medications

In this episode, the Brach Eichler Healthcare Law team breaks down the federal government’s newly announced agreement with Eli Lilly and Novo Nordisk to dramatically reduce the cost of popular GLP-1 medications—including Ozempic, Wegovy, Zepbound, and future oral GLP-1 tablets. We explore what this landmark deal means for Medicare and Medicaid beneficiaries, cash-pay patients, and healthcare providers, as well as its connection to the administration’s Most-Favored-Nation drug pricing initiative.

Our attorneys explain key price changes, the launch of the TrumpRx purchasing platform, expanded obesity-drug coverage under Medicare, and pharmaceutical manufacturers’ massive U.S.-based investments.

Tune in for clear, practical insights on how these policy shifts may impact prescribing, patient access, and the broader healthcare delivery landscape.

📲 Read the full article now at https://www.bracheichler.com/insights/feds-pharma-companies-strike-deal-for-low-cost-glp-1-medications/

For more information, contact: John D. Fanburg, Chair – 973.403.3107 – [e-mail] Richard B. Robins – 973.447.9663 – [e-mail] Andrew M. Kuder – 973.403.3141 – [e-mail]

*This is intended to provide general information, not legal advice. Please contact the authors if you need specific legal advice.

Episode Transcript

(00:00):
Thank you for tuning in to the Brach Eichler Talks podcast,

(00:06):
where we explore and discuss today's trending legal topics.
In this episode, we'll discuss a recent article from Brach Eichler's December Healthcare Law
Update titled, "Feds Pharma Companies Strike Deal for Low Cost GLP one Medications." On
November 6th, 2025, the Trump administration announced a landmark agreement with

(00:27):
pharmaceutical manufacturers Eli Lilly and Novo Nordisk to provide steep discounts on their most
popular GLP-1 medications, cuts that will benefit
Medicare and Medicaid enrollees as well as cash paying patients.
Under the agreement, prices for drugs like Ozempic, Wegovy, Zepbound, and future GLP-1
tablets will drop to an average of $149 to $350 per month, a dramatic decline from the current

(00:52):
cost of $500 to $1,000 or more for many U.S.
patients. The agreement delivers on a key goal of the current administration's
Most-Favored-Nation (MFN) drug pricing initiative, which aims to bring U.S.
prescription drug prices in line with, or below, those paid in other developed countries.
The agreement is part of a broader administration strategy to end what it describes as "global

(01:17):
freeloading"… -where Americans pay far more for drugs than consumers in other countries.

Some highlights of the deal include (01:23):
injectable GLP-1s like Ozempic and Wegovy will be
available via the government's new TrumpRX purchasing platform at $350 per month, down from
$1,000-$1,350 per month; if approved, oral GLP-1 tablets (like Eli Lilly's orforglipron) will
launch at around one hundred forty nine dollars per month through TrumpRX; and, for Medicare

(01:45):
beneficiaries, drugs like Wegovy and Zepbound will be covered for obesity under certain
conditions and beneficiaries will pay just $50 per month in co-pays.
In addition to GLP-1 products, Eli Lilly will offer its Trulicity diabetes drug at $389 per
month, and Novo Nordisk will price its insulin products (like NovoLog and Tresiba) at $35 per month.

(02:08):
The companies are also pledging to repatriate foreign revenues and guarantee MFN pricing on all
future (and some existing) products, giving state Medicaid
programs access to these lower, globally competitive drug costs.
To support this effort, both companies are making significant U.S .-based investments.
Novo Nordisk has committed to invest $10 billion dollars to expand domestic production,

(02:32):
including building capacity for a future Wegovy tablet, and Eli Lilly has committed $27 billion dollars to U.S.
manufacturing infrastructure. For more information, contact John D.
Fanburg, Member and Chair, Healthcare Law at 973-403-3107 or
[e-mail] or Richard B.
Robins, Member, Healthcare Law at 973-447-9663 or [e-mail] or Andrew M.

(02:57):
Kuder, Associate, Healthcare Law at 973-403-3141 or [e-mail].
Don't forget to subscribe to our podcast on Spotify, Apple Podcasts, and YouTube.
Follow us on LinkedIn and Facebook for updates on new episodes.
For more information and resources, visit Brach eichler dot com.

(03:18):
This is intended to provide general information, not legal advice.
Please contact the authors if you need specific legal advice.
Brach Eichler LLC is a full service law firm based in Roseland, New Jersey with over eighty attorneys.
The firm is focused on the following practice areas, health care law, real estate, litigation

(03:38):
, trusts and estates, business transactions and financial services, personal injury, criminal
defense and government investigations, labor and employment, environmental and land use,
family law services, patent, intellectual property, and
information technology, real estate tax appeals, tax, and cannabis